MedElevator Войти в исследования
← Поиск публикаций

DOI 10.20517/cdr.2024.173

Медицинская библиотека · Cancer drug resistance (Alhambra, Calif.) · 2025

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches.

Khorasanchi Adam, Hong Feng, Yang Yuanquan, Singer Eric A, Wang Peng, Li Mingjia, Zheng Linghua, Monk Paul, Mortazavi Amir, Meng Lingbin

СтатьяОбзорПеревод в очереди

Аннотация

Metastatic castration-resistant prostate cancer (mCRPC) is driven by a complex network of resistance mechanisms against standard-of-care therapies, resulting in poor long-term outcomes. This review offers a uniquely comprehensive and integrative perspective on these resistance pathways, systematically examining both androgen receptor (AR)-dependent factors (including AR overexpression, point mutations, glucocorticoid receptor signaling, splice variants, post-translational modifications, altered coregulators, and intratumoral hormone biosynthesis) and AR-independent pathways (such as neuroendocrine differentiation, lineage plasticity, and alternative growth factor signaling). We also highlight resistance mechanisms influencing immunotherapy, chemotherapy, radiopharmaceutical therapy and targeted therapy. By synthesizing emerging insights across these domains, this review not only clarifies the underlying biology of mCRPC resistance but also identifies key leverage points for more effective interventions. Building on this foundation, we propose a forward-looking framework for overcoming mCRPC drug resistance, emphasizing the importance of biomarker-guided patient selection, combination strategies that simultaneously target multiple resistance mechanisms, and novel therapies under investigation. These recommendations are intended to guide future clinical trial designs and research priorities that move beyond incremental improvements. Ultimately, this comprehensive synthesis aims to serve as a resource for clinicians and researchers to accelerate the development of durable, precision-based treatment strategies in mCRPC.

Для цитирования: Khorasanchi Adam, Hong Feng, Yang Yuanquan, Singer Eric A, Wang Peng, Li Mingjia, Zheng Linghua, Monk Paul, Mortazavi Amir, Meng Lingbin. Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches.. Cancer drug resistance (Alhambra, Calif.). 2025. DOI: 10.20517/cdr.2024.173.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.